..."Worst of all for Big Brown’s connections, perhaps, were the questions about steroids. Dutrow told The New York Times last week that Big Brown had not had his usual shot of the anabolic steroid Winstrol since April 15, enough time for the drug to leave his system. Was Big Brown’s poor performance because of his lack of “juice?” “He wasn’t on steroids for the Preakness,” Iavarone said. “There is a million things that could have got him beat. If people are going to say that no Winstrol got him beat, they are going to say that.” Zito made it clear that the questions about steroids and other drugs in horse racing had put a damper on his second Belmont triumph and fifth Triple Crown victory over all in what is a Hall of Fame career. “The lords of horse racing need to get together and make some rules that we all abide by,” he said. “It’s a big issue and we can’t ignore it, and we need to get past it.” Before the race, Zito declined to say if his two horses in the Belmont, including Anak Nakal, who tied for third, would be on steroids. On Sunday, he also declined to say if his horses had received steroids. In the wake of Eight Belles’s fatal injuries after finishing second in the Kentucky Derby, and Dutrow’s frank discussion of pharmaceuticals over the course of the Triple Crown, there appears to be a groundswell of support in the industry to ban steroids and prohibit race-day medications."..."If he had become the first to sweep the series since Affirmed in 1978, Big Brown would have been expected to stand for at least $200,000 a mating and, as the only living Triple Crown champion, would have been worth up to $120 million. Instead, I.E.A.H. and Big Brown’s other co-owners are going to be hard pressed to restore the colt’s stallion market to perhaps half of that $60 million level. "...

..."Worst of all for Big Brown’s connections, perhaps, were the questions about steroids. Dutrow told The New York Times last week that Big Brown had not had his usual shot of the anabolic steroid Winstrol since April 15, enough time for the drug to leave his system. Was Big Brown’s poor performance because of his lack of “juice?” “He wasn’t on steroids for the Preakness,” Iavarone said. “There is a million things that could have got him beat. If people are going to say that no Winstrol got him beat, they are going to say that.” Zito made it clear that the questions about steroids and other drugs in horse racing had put a damper on his second Belmont triumph and fifth Triple Crown victory over all in what is a Hall of Fame career. “The lords of horse racing need to get together and make some rules that we all abide by,” he said. “It’s a big issue and we can’t ignore it, and we need to get past it.” Before the race, Zito declined to say if his two horses in the Belmont, including Anak Nakal, who tied for third, would be on steroids. On Sunday, he also declined to say if his horses had received steroids. In the wake of Eight Belles’s fatal injuries after finishing second in the Kentucky Derby, and Dutrow’s frank discussion of pharmaceuticals over the course of the Triple Crown, there appears to be a groundswell of support in the industry to ban steroids and prohibit race-day medications."..."If he had become the first to sweep the series since Affirmed in 1978, Big Brown would have been expected to stand for at least $200,000 a mating and, as the only living Triple Crown champion, would have been worth up to $120 million. Instead, I.E.A.H. and Big Brown’s other co-owners are going to be hard pressed to restore the colt’s stallion market to perhaps half of that $60 million level. "...

..."Worst of all for Big Brown’s connections, perhaps, were the questions about steroids. Dutrow told The New York Times last week that Big Brown had not had his usual shot of the anabolic steroid Winstrol since April 15, enough time for the drug to leave his system. Was Big Brown’s poor performance because of his lack of “juice?” “He wasn’t on steroids for the Preakness,” Iavarone said. “There is a million things that could have got him beat. If people are going to say that no Winstrol got him beat, they are going to say that.” Zito made it clear that the questions about steroids and other drugs in horse racing had put a damper on his second Belmont triumph and fifth Triple Crown victory over all in what is a Hall of Fame career. “The lords of horse racing need to get together and make some rules that we all abide by,” he said. “It’s a big issue and we can’t ignore it, and we need to get past it.” Before the race, Zito declined to say if his two horses in the Belmont, including Anak Nakal, who tied for third, would be on steroids. On Sunday, he also declined to say if his horses had received steroids. In the wake of Eight Belles’s fatal injuries after finishing second in the Kentucky Derby, and Dutrow’s frank discussion of pharmaceuticals over the course of the Triple Crown, there appears to be a groundswell of support in the industry to ban steroids and prohibit race-day medications."..."If he had become the first to sweep the series since Affirmed in 1978, Big Brown would have been expected to stand for at least $200,000 a mating and, as the only living Triple Crown champion, would have been worth up to $120 million. Instead, I.E.A.H. and Big Brown’s other co-owners are going to be hard pressed to restore the colt’s stallion market to perhaps half of that $60 million level. "...

..."Aggressive, AAS-treated hamsters showed significant decreases in the area covered by 5HT1B-containing neuronal puncta and increases in the number of 5HT1B-containing neuronal somata in select brain regions implicated in aggression control. Together, these data support a role for site-specific alterations in 5HT1B signaling and expression in adolescent AAS-induced aggression. "

.."Interestingly, hormones with completely different physiological effects can produce similar withdrawal syndromes, whereas some of the clinical manifestations that are due to the chronic presence of high hormone levels or withdrawal syndromes are also observed with drugs of abuse. This review postulates that changes of the hypothalamic-pituitary-adrenal (HPA) axis and the central opioid peptide, noradrenergic and dopaminergic systems act as shared features in the pathogenesis of several endocrine withdrawal syndromes. The molecular and cellular bases of endocrine or drug-related addiction and withdrawal syndromes, however, are poorly understood. The best established molecular and cellular mechanisms of short- and long-term adaptation to hormones or allostasis induced by drugs of abuse is potentiation of G protein receptor coupling, up-regulation of cAMP, increased activities of protein kinases, and changes in the expression and activities of several transcription factors. The withdrawal syndrome after glucocorticoid discontinuation has drawn a great deal of attention over the years and has been studied extensively. We suggest that the symptoms and signs that occur after cessation of administration of several other hormones may also comprise a similar withdrawal syndrome. These other hormones have not been studied as thoroughly as the glucocorticoids, and the following discussion refers primarily to animal studies and clinical inferences from such studies. Whereas some of the observations and suggestions are scientifically evident and valid, based on solid data in both animals and humans, other annotations are tentative or speculative, lacking evidence from well-designed clinical studies. Further clinical research needs to take place before these suggestions are implemented. "..."Withdrawal syndrome in athletes abusing androgens .....Problems with drug withdrawal and dependence may result in decreased sexual drive, but also in a flu-like syndrome that mimics in many ways the glucocorticoid withdrawal syndrome (123). Fatigue, muscle and joint pain, headache, and insomnia are followed by a second phase of depression (124), a condition that appears to be more common than previously realized (125). As many as 23% of users reported major mood syndromes: mania, hypomania, and depression probably occur as a result of the episodic nature of use and discontinuation of anabolic steroids (117). Androgen withdrawal is often associated with the desire to resume steroid consumption ("craving") (124). These symptoms and signs are obviously unrelated to specific symptoms and signs of androgen deficiency, as they manifest in patients with hyper- or hypogonadotrophic hypogonadism. "...

"Abuse of androgenic anabolic steroids can affect brain function leading to behavioural changes. In this study, the effects of the testosterone analogue, 19-nortestosterone, on rat neural stem cells was examined."..."The results show that nandrolone has important effects on the proliferation and differentiation of neural stem cells expressing the cognate androgen receptor. The data show that the use of nandrolone may severely affect the formation of neural stem cells and could therefore have long-term negative consequences in the brain."